The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study
Open accessAbstract
BACKGROUND: Activated phosphoinositide 3-kinase δ syndrome (APDS) is a recently described combined immunodeficiency resulting from gain-of-function mutations in PIK3CD, the gene encoding the catalytic subunit of phosphoinositide 3-kinase δ (PI3Kδ). OBJECTIVE: We sought to review the clinical, immunologic, histopathologic, and radiologic features of APDS in a large genetically defined international cohort. METHODS: We applied a clinical questionnaire and performed review of medical notes, radiology, histopathology, and laboratory investigations of 53 patients with APDS. RESULTS: Recurrent sinopulmonary infections (98%) and nonneoplastic lymphoproliferation (75%) were common, often from childhood. Other significant complications included herpesvirus infections (49%), autoinflammatory disease (34%), and lymphoma (13%). Unexpectedly, neurodevelopmental delay occurred in 19% of the cohort, suggesting a role for PI3Kδ in the central nervous system; consistent with this, PI3Kδ is broadly expressed in the developing murine central nervous system. Thoracic imaging revealed high rates of mosaic attenuation (90%) and bronchiectasis (60%). Increased IgM levels (78%), IgG deficiency (43%), and CD4 lymphopenia (84%) were significant immunologic features. No immunologic marker reliably predicted clinical severity, which ranged from asymptomatic to death in early childhood. The majority of patients received immunoglobulin replacement and antibiotic prophylaxis, and 5 patients underwent hematopoietic stem cell transplantation. Five patients died from complications of APDS. CONCLUSION: APDS is a combined immunodeficiency with multiple clinical manifestations, many with incomplete penetrance and others with variable expressivity. The severity of complications in some patients supports consideration of hematopoietic stem cell transplantation for severe childhood disease. Clinical trials of selective PI3Kδ inhibitors offer new prospects for APDS treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fleischner Society: Glossary of Terms for Thoracic Imaging
Hansell, D. M., Bankier, A. A., MacMahon, H., McLoud, T. C., Müller, N. L., & Remy, J. (2008) · Radiology · doi:10.1148/radiol.2462070712 · Cited by 4,198
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315226 · Cited by 1,710
Common Variable Immunodeficiency: Clinical and Immunological Features of 248 Patients
Cunningham-Rundles, C., & Bodian, C. (1999) · Clinical Immunology · doi:10.1006/clim.1999.4725 · Cited by 1,516
Picard, C., Al-Herz, W., Bousfiha, A., Casanova, J.-L., Chatila, T., Conley, M. E., Cunningham-Rundles, C., Etzioni, A., Holland, S. M., Klein, C., et al. (2015) · Journal of Clinical Immunology · doi:10.1007/s10875-015-0201-1 · Cited by 1,197
Self-citationPI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Gopal, A. K., Kahl, B. S., de Vos, S., Wagner-Johnston, N. D., Schuster, S. J., Jurczak, W. J., Flinn, I. W., Flowers, C. R., Martin, P., Viardot, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314583 · Cited by 1,069
Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice
Okkenhaug, K., Bilancio, A., Farjot, G., Priddle, H., Sancho, S., Peskett, E., Pearce, W., Meek, S. E., Salpekar, A., Waterfield, M. D., et al. (2002) · Science · doi:10.1126/science.1073560 · Cited by 946
Self-citationCommon variable immunodeficiency disorders: division into distinct clinical phenotypes
Chapel, H., Lucas, M., Lee, M., Bjorkander, J., Webster, D., Grimbacher, B., Fieschi, C., Thon, V., Abedi, M. R., & Hammarstrom, L. (2008) · Blood · doi:10.1182/blood-2007-11-124545 · Cited by 835
Self-citationAl-Herz, W., Bousfiha, A., Casanova, J.-L., Chatila, T., Conley, M. E., Cunningham-Rundles, C., Etzioni, A., Franco, J. L., Gaspar, H. B., Holland, S. M., et al. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00162 · Cited by 748
Self-citationImmunophenotyping of blood lymphocytes in childhoodReference values for lymphocyte subpopulations
Comans-Bitter, W. M., de Groot, R., van den Beemd, R., Neijens, H. J., Hop, W. C. J., Groeneveld, K., Hooijkaas, H., & van Dongen, J. J. M. (1997) · The Journal of Pediatrics · doi:10.1016/s0022-3476(97)70200-2 · Cited by 727
Lucas, C. L., Kuehn, H. S., Zhao, F., Niemela, J. E., Deenick, E. K., Palendira, U., Avery, D. T., Moens, L., Cannons, J. L., Biancalana, M., et al. (2014) · Nature Immunology · doi:10.1038/ni.2771 · Cited by 673
Cited by
PI3K isoforms in cell signalling and vesicle trafficking
Bilanges, B., Posor, Y., & Vanhaesebroeck, B. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0129-z · Cited by 525
Self-citationPI3K inhibitors are finally coming of age
Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., André, F., & Okkenhaug, K. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00209-1 · Cited by 476
Self-citationOncogenic Roles of the PI3K/AKT/mTOR axis
Aoki, M., & Fujishita, T. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_6 · Cited by 355
Chalmers, J. D., Chang, A. B., Chotirmall, S. H., Dhar, R., & McShane, P. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0042-3 · Cited by 351
PI3Kδ and primary immunodeficiencies
Lucas, C. L., Chandra, A., Nejentsev, S., Condliffe, A. M., & Okkenhaug, K. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.93 · Cited by 342
Self-citation
Metadata
- Authors
- Coulter, T. I., Chandra, A., Bacon, C. M., Babar, J., Curtis, J., Screaton, N., Goodlad, J. R., Farmer, G., Steele, C. L., Leahy, T. R., Doffinger, R., Baxendale, H., Bernatoniene, J., Edgar, J. D. M., Longhurst, H. J., Ehl, S., Speckmann, C., Grimbacher, B., Sediva, A., Milota, T., Faust, S. N., Williams, A. P., Hayman, G., Kucuk, Z. Y., Hague, R., French, P., Brooker, R., Forsyth, P., Herriot, R., Cancrini, C., Palma, P., Ariganello, P., Conlon, N., Feighery, C., Gavin, P. J., Jones, A., Imai, K., Ibrahim, M. A. A., Markelj, G., Abinun, M., Rieux-Laucat, F., Latour, S., Pellier, I., Fischer, A., Touzot, F., Casanova, J.-L., Durandy, A., Burns, S. O., Savic, S., Kumararatne, D. S., Moshous, D., Kracker, S., Vanhaesebroeck, B., Okkenhaug, K., Picard, C., Nejentsev, S., Condliffe, A. M., & Cant, A. J.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 139
- Issue
- 2
- Pages
- 597-606.e4
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2513184125
- Cited by
- 453
- References
- 38
- FWCI
- 23.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study. https://app.cochat.ai/papers/10.1016/j.jaci.2016.06.021
- The paper
- Coulter, T. I., Chandra, A., Bacon, C. M., Babar, J., Curtis, J., Screaton, N., Goodlad, J. R., Farmer, G., Steele, C. L., Leahy, T. R., Doffinger, R., Baxendale, H., Bernatoniene, J., Edgar, J. D. M., Longhurst, H. J., Ehl, S., Speckmann, C., Grimbacher, B., Sediva, A., . . . Cant, A. J. (2017). Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2016.06.021
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.